Skip to content

H2020FP7HORIZON

Astrazeneca AB

Country
SESweden
Defence projects
0
Projects, all programmes
150
As coordinator
8
EU contribution (CORDIS)
EUR 17,186,814
Active
2008 to 2026

Projects

150 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
MIRACLEMultilevel inflammatory regulation in cardiometabolic diseaseHORIZON2024Associated partnerEUR 0
CirculH2Hydrogenases for Large Scale Deployment of H2 as a Circular Energy Carrier in Industrial Biotechnology Based on Enzymatic CatalystsHORIZON2024ParticipantEUR 230,125
iCARE4CVDINDIVIDUALISED CARE FROM EARLY RISK OF CARDIOVASCULAR DISEASE TO ESTABLISHED HEART FAILUREHORIZON2023ParticipantEUR 0
BiodeCCodiNNgDecoding novel reaction chemistries in biocatalysis – Training Europe’s next visionaries for a sustainable futureHORIZON2023Associated partnerEUR 0
ISOBIOTICSIsotopic Labeling of BiotherapeuticsHORIZON2023ParticipantEUR 587,419
AiRPaDDAdvancing Reaction Platforms for Drug DiscoveryHORIZON2023ParticipantEUR 244,758
SCALEIndustry empowerment to Multiphase fluid dynamics simulations using Artificial intelligence and Statistical methods on modern hardware architectures at ScaleHORIZON2023Associated partnerEUR 0
AiChemistExplainable AI for Molecules - AiChemistHORIZON2023ParticipantEUR 587,419
MMMMedicine Made to Measure.HORIZON2023Associated partnerEUR 0
PRISMASPhD Research and Innovation in Synchrotron Methods and Applications in SwedenHORIZON2023Associated partnerEUR 0
IDProIntrinsically disordered proteins in health and disease: mechanisms, molecular context and opportunities for drug discoveryHORIZON2023Associated partnerEUR 0
FACILITATEFrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystemH20202022ParticipantEUR 0
GetRadiGene Therapy of Rare DiseasesHORIZON2022ParticipantEUR 587,419
LiverTargetNext generation advanced RNA inhibition therapy to treat cardiometabolic diseaseHORIZON2022ParticipantEUR 50,000
EDITSCDAssessing efficacy and safety of genome EDITing approaches for Sickle Cell DiseaseHORIZON2022ParticipantEUR 520,000
PROMISEPreparing for RSV Immunisation and Surveillance in EuropeH20202021ParticipantEUR 0
OLIGOMEDOligonucleotides for Medical ApplicationsH20202021ParticipantEUR 281,983
RealHOPEReal World Handling of Protein Drugs - Exploration, Evaluation and EducationH20202021ParticipantEUR 0
InPharmaA fully integrated, animal-free, end-to-end modelling approach to oral drug product developmentH20202021ParticipantEUR 140,991
ENLIGHTENable LIGHT- and synthetic biology-driven volumetric bioprinting of functional human tissuesH20202021ParticipantEUR 278,000

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.